Siemens Healthineers stock faces cautious 2027 outlook after strong Q4

Siemens Healthineers reported a strong fourth quarter on Thursday, November 5, 2026, but set a more cautious financial framework for fiscal 2027. The company said in its fiscal 2026 results release that comparable quarterly revenue grew 5.9 percent.

At 17:09 CET on Thursday, Siemens Healthineers stock traded at 45.08 euros on Lang & Schwarz, 0.51 percent above the Xetra close of Wednesday, November 4, at 44.85 euros. The quote was 3.04 percent above the 43.75 euros reported in the previous same-day coverage at 11:07 CET, highlighting a fresh market move after the results.

Imaging offsets Diagnostics pressure

Fourth-quarter revenue reached 6.784 billion euros, up 7.3 percent from the prior year. Adjusted basic earnings per share came to 0.69 euros, while free cash flow reached 703 million euros and the equipment book-to-bill ratio was 1.15.

Imaging led the operating performance with comparable revenue growth of 10.0 percent and an adjusted EBIT margin of 21.9 percent. Precision Therapy grew 4.8 percent on a comparable basis. Diagnostics, by contrast, recorded a 4.2 percent comparable revenue decline and an adjusted EBIT margin of 5.4 percent. Group adjusted EBIT margin was 15.9 percent.

Guidance points to slower earnings

For fiscal 2027, management expects comparable revenue growth of 4.0 to 5.0 percent. Adjusted basic earnings per share are forecast at 2.20 to 2.40 euros, below the 2.42 euros reported for fiscal 2026. The company proposed an unchanged dividend of 1.00 euro per share.

The outlook leaves execution in Imaging and a stabilization of Diagnostics as key investor focus areas. The company also said it is initiating the Diagnostics carve-out process and plans to evolve its brand and name to Healthineers. The Morningstar company profile identifies Siemens Healthineers as a healthcare and medical-devices business.

Follow the real-time quote of Siemens Healthineers stock for the latest trading level.

The broader German market can be followed through current DAX market developments.

More news and analyses on Siemens Healthineers stock